J&J in $1 Billion Deal to Bolster Prostate-Cancer Focus

18.06.2013 - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired...